FrancophonIA/ELRC3.0 huggingface dataset:
English: IVEMEND should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5).
Croatian: IVEMEND se mora primjenjivati uz oprez u bolesnika koji istodobno primaju lijekove koji se metaboliziraju prvenstveno putem CYP3A4 i imaju uski terapijski indeks, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, derivati ergot alkaloida, fentanil i kinidin (vidjeti dio 4.5).
English: Single day chemotherapy regimens include those regimens in which HEC or MEC is administered for a single day only.
Croatian: Jednodnevni kemoterapijski režimi uključuju one režime u kojima se jako ili umjereno emetogena kemoterapija primjenjuje samo jedan dan.
English: Table 2: Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy regimen in adults
Croatian: Tablica 2: Preporučeno doziranje za prevenciju mučnine i povraćanja povezanih s umjereno emetogenim režimom kemoterapije u odraslih
English: In a juvenile toxicity study in rats treated with aprepitant from postnatal day 10 to day 63, earlier vaginal opening in females from 250 mg/kg b.i.d.
Croatian: U ispitivanju toksičnosti u mladih štakora tretiranih aprepitantom postnatalno od 10. do 63. dana, zabilježeno je preuranjeno vaginalno otvaranje u ženki pri primjeni od 250 mg/kg dvaput na dan, te odgođeno odvajanje prepucija u mužjaka pri primjeni od 10 mg/kg dvaput na dan.
English: Fosaprepitant, a prodrug of aprepitant, when administered intravenously is rapidly converted to aprepitant.
Croatian: Fosaprepitant je prolijek aprepitanta koji nakon intravenske primjene vrlo brzo prelazi u aprepitant.
English: Necrosis was also reported in some patients with concomitant vesicant chemotherapy.
Croatian: U nekih bolesnika koji su istodobno primali kemoterapiju vezikantom prijavljena je i nekroza.
English: Each vial contains 150 mg of fosaprepitant.
Croatian: Jedna bočica sadrži 150 mg fosaprepitanta.
English: Uncommon side effects (may affect up to 1 in 100 people) are: - dizziness, sleepiness, - acne, rash, - anxiousness, - burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind, - increased painful or burning urination, - weakness, generally feeling unwell, - reddening of the face/skin, hot flush, - fast or irregular heartbeats, blood pressure increased,
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba) su: - omaglica, pospanost, - akne, svrbež, - tjeskoba, - podrigivanje, mučnina, povraćanje, žgaravica, bol u trbuhu, suha usta, vjetrovi, - učestalo bolno mokrenje ili mokrenje uz osjećaj pečenja, - slabost, opće loše osjećanje, - crvenilo lica i kože, navale vrućine, - brzi ili nepravilni otkucaji srca, povišen krvni tlak, - vrućica s povećanim rizikom od infekcije, pad broja crvenih krvnih stanica,
English: In rabbits, fosaprepitant caused initial transient local acute inflammation following paravenous, subcutaneous and intramuscular administration.
Croatian: U kunića je fosaprepitant nakon paravenske, supkutane i intramuskularne primjene uzrokovao prolaznu lokalnu akutnu upalu.
English: Paediatric Patients Receiving 1-Day Fosaprepitant Regimen The efficacy of the 1-day fosaprepitant regimen in paediatric patients was extrapolated from that demonstrated in adults receiving the 1-day fosaprepitant regimen as described in the 1-Day Regimen of Fosaprepitant in Adults subsection.
Croatian: Djelotvornost jednodnevnog režima fosaprepitanta u pedijatrijskih bolesnika ekstrapolirana je iz one dokazane u odraslih koji su primili jednodnevni režim fosaprepitantom kako je opisano u dijelu o jednodnevnom režimu fosaprepitanta u odraslih.
English: See selected 5-HT3 antagonist prescribing information for the recommended dosage
Croatian: Vidjeti informacije o propisivanju odabranog antagonista 5-HT3 za preporučeno doziranje
English: The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with IVEMEND.
Croatian: Pri istodobnoj primjeni s lijekom IVEMEND potrebno je razmotriti mogući učinak na povišenje koncentracije midazolama i drugih benzodiazepina koji se metaboliziraju putem CYP3A4 (alprazolama, triazolama) u plazmi.
English: Additional adverse reactions were observed in adult patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Croatian: Sljedeće nuspojave zabilježene su češće u odraslih bolesnika koji su primali aprepitant zbog postoperativne mučnine i povraćanja (engl. postoperative nausea and vomiting, PONV) nego u bolesnika koji su primali ondanzetron: bol u gornjem dijelu abdomena, neobični zvukovi u crijevima, konstipacija*, dizartrija, dispneja, hipoestezija, nesanica, mioza, mučnina, poremećaji osjeta, nelagoda u trbuhu, sub-ileus*, smanjena oštrina vida, piskanje u plućima.
English: Assure that sodium chloride 9 mg/ml (0.9 %) solution for injection is added to the vial along the vial wall in order to prevent foaming.
Croatian: Pazite da 0,9%-tnu (9 mg/ml) otopinu natrijeva klorida za injekciju dodajete niz stijenku bočice kako se ne bi pjenila.
English: There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment.
Croatian: Saznanja o bolesnicima s umjerenim oštećenjem funkcije jetre su ograničena, a nema podataka o bolesnicima s teškim oštećenjem funkcije jetre.
English: Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction), - euphoria (feeling of extreme happiness), disorientation, - bacterial infection, fungal infection, - severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating, - frequent urination, passing more urine than normal, presence of sugar or blood in urine, - chest discomfort, swelling, change in the manner of walking, - cough, mucus in back of throat, throat irritation, sneezing, sore throat, - eye discharge and itching, - ringing in the ear, - muscle spasms, muscle weakness, - excessive thirst, - slow heartbeat, heart and blood vessel disease, - lowering of white blood cells, low sodium levels in the blood, weight loss, - hardening of site of infusion.
Croatian: Rijetke nuspojave (mogu se javiti u do 1 na 1000 osoba) su: - poteškoće pri razmišljanju, nedostatak energije, promijenjeni osjet okusa, - osjetljivost kože na sunce, prekomjerno znojenje, masna koža, ranice na koži, osip praćen svrbežom, Stevens-Johnsonov sindrom/toksična epidermalna nekroliza (rijetka ozbiljna kožna reakcija), - euforija (izraženi osjećaj sreće), gubitak orijentacije, - bakterijska infekcija, gljivična infekcija, - teški zatvor, vrijed na želucu, upala tankog i debelog crijeva, afte u ustima, nadutost, - često mokrenje, veća količina mokraće nego obično, prisutnost šećera ili krvi u mokraći - osjećaj nelagode u prsnom košu, oticanje, promjene u načinu hoda, - kašalj, cijeđenje sluzi iz nosa u grlo, nadraženo grlo, kihanje, upala grla, - iscjedak i svrbež u oku, - zujanje u uhu, - grčevi u mišićima, mišićna slabost, - prekomjerna žeđ, - usporeni otkucaji srca, bolest srca i krvnih žila, - pad broja bijelih krvnih stanica, niske razine natrija u krvi, gubitak tjelesne težine, - otvrdnuće na mjestu infuzije.
English: C]- fosaprepitant to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.
Croatian: Nakon jednokratne intravenske primjene C]-fosaprepitanta u dozi od 100 mg u zdravih osoba, 57% radioaktivnosti nađe se u mokraći, a 45% u fecesu.
English: Renal impairment: A single 240 mg dose of oral aprepitant was administered to patients with severe renal impairment (CrCl< 30 ml/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.
Croatian: Oštećenje funkcije bubrega: Bolesnici s teškim oštećenjem funkcije bubrega (CrCl < 30 ml/min), i bolesnici s bolešću bubrega u završnom stadiju (ESRD-om) na hemodijalizi primili su jednokratnu dozu od 240 mg peroralnog aprepitanta.
English: The powder is reconstituted and diluted before use.
Croatian: Prije uporabe prašak treba pripremiti za primjenu i razrijediti.
English: The adverse reactions profiles in the Multiple-Cycle extension of HEC and MEC studies in adults for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1.
Croatian: Profil nuspojava u višekratnim ciklusima produžetka ispitivanja u odraslih u jako i umjereno emetogenoj kemoterapiji (najviše šest) uglavnom je bio sličan onom zabilježenom u prvom ciklusu kemoterapije.
English: Fosaprepitant 150 mg is a weak CYP3A4 inhibitor as a single dose on Day 1 with no evidence of inhibition or induction of CYP3A4 observed on Day 4.
Croatian: Fosaprepitant 150 mg primijenjen u jednokratnoj dozi 1. dana liječenja je slab inhibitor CYP3A4, a 4. dana liječenja nije opažena ni inhibicija ni indukcija CYP3A4.
English: Oral aprepitant
Croatian: Peroralni aprepitant
English: The efficacy of a 1-day fosaprepitant regimen in paediatric patients is expected to be similar to that of the 1-day adult fosaprepitant regimen.
Croatian: Očekuje se da će djelotvornost jednodnevnog režima fosaprepitanta u pedijatrijskih bolesnika biti slična djelotvornosti jednodnevnog režima fosaprepitanta u odraslih.
English: Table 3.
Croatian: Tablica 3:
English: AST increased, blood alkaline phosphatase increased uncommon red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased rare
Croatian: često povišene vrijednosti AST, povišene vrijednosti alkalne fosfataze manje često eritrociti u urinu, hiponatrijemija, gubitak tjelesne težine, smanjeni broj neutrofila, glukoza u urinu, učestalo mokrenje rijetko
English: The reconstituted and diluted medicinal product should be inspected visually for particulate matter and discoloration before administration.
Croatian: Rekonstituirani i razrijeđeni lijek treba dobro pregledati prije primjene da ne sadrži čestice i da nije došlo do promjene boje.
English: The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving MEC was fatigue (1.4 % versus 0.9 %).
Croatian: Umor je bio najčešća nuspojava prijavljena s većom incidencijom u bolesnika na umjereno emetogenoj kemoterapiji koji su uzimali aprepitant nego u bolesnika na standardnoj terapiji (1,4% u odnosu na 0,9%).
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the last dose of fosaprepitant (see sections 4.4 and 4.5).
Croatian: Dok traje liječenje fosaprepitantom i dva mjeseca nakon uzimanja posljednje doze fosaprepitanta treba dodatno koristiti zamjenske nehormonske metode kontracepcije (vidjeti dio 4.4 i 4.5).
English: §Overall = 0 to 120 hours post-initiation of cisplatin chemotherapy.
Croatian: Ukupno = 0 do 120 sati nakon započinjanja kemoterapije cisplatinom.
English: See the product information for the selected 5-HT3 antagonist for appropriate dosing information none none none
Croatian: Za pravilno doziranje vidjeti uputu o lijeku odabranih 5-HT3 antagonista ništa ništa ništa
English: Table 8: Percent of adult patients receiving Moderately Emetogenic Chemotherapy responding by treatment group and phase
Croatian: Postotak odraslih bolesnika koji su primali umjereno emetogenu kemoterapiju i imali odgovor prikazani prema terapijskim skupinama i fazama
English: Skin and subcutaneous tissue disorders erythema uncommon
Croatian: Poremećaji kože i potkožnog tkiva eritem manje često
English: Inject 5 ml sodium chloride 9 mg/ml (0.9 %) solution for injection into the vial.
Croatian: U bočicu injekcijom ubrizgajte 5 ml 0,9%-tne (9 mg/ml) otopine natrijeva klorida za injekciju.
English: Highly Emetogenic Chemotherapy (HEC)
Croatian: Highly Emetogenic Chemotherapy , HEC) ili umjereno emetogenom kemoterapijom (engl.
English: Day 2
Croatian: 2. dan
English: Gastrointestinal disorders constipation, dyspepsia common eructation, nausea*, vomiting*, gastroesophageal reflux disease, abdominal pain, dry mouth, flatulence uncommon duodenal ulcer perforation, stomatitis, abdominal distension, faeces hard, neutropenic colitis rare
Croatian: Poremećaji probavnog sustava konstipacija, dispepsija često podrigivanje, mučnina*, povraćanje*, gastroezofagealna refluksna bolest, bol u abdomenu, suha usta, nadutost manje često perforacija vrijeda na dvanaesniku, stomatitis, distenzija abdomena, tvrda stolica, neutropenični kolitis rijetko
English: Tabulated list of adverse reactions - fosaprepitant The following are adverse reactions reported in adult patients receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above.
Croatian: Sljedeće nuspojave prijavljene su u odraslih bolesnika koji su primali fosaprepitant u kliničkim ispitivanjima te u razdoblju nakon stavljanja lijeka u promet, a koje nisu zabilježene uz primjenu aprepitanta i već navedene u prethodnoj tablici.
English: ‡ Delayed phase = 25 to 120 hours post-initiation of chemotherapy.
Croatian: ‡ Kasnija faza = 25 do 120 sati nakon započinjanja kemoterapije.
English: Day 3
Croatian: 3. dan
English: - fever with increased risk of infection, lowering of red blood cells, - infusion site pain, infusion-site redness, infusion-site itching, infusion site vein inflammation.
Croatian: - bol na mjestu infuzije, crvenilo na mjestu infuzije, svrbež na mjestu infuzije, upala vene na mjestu infuzije.
English: Disodium edetate, polysorbate 80, lactose anhydrous, NaOH and/or HCl diluted (for pH adjustment).
Croatian: Dinatrijev edetat, polisorbat 80, laktoza, bezvodna, natrijev hidroksid i/ili kloridna kiselina, razrijeđena (za podešavanje pH)
English: §Overall = 0 to 120 hours post-initiation of chemotherapy.
Croatian: §Ukupno = 0 do 120 sati nakon započinjanja kemoterapije.
English: CARTON 150 mg
Croatian: KARTONSKA KUTIJA 150 mg
English: Fosaprepitant regimen (N =502) **
Croatian: (N =502) **
English: Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC0-∞ of midazolam by 77 % on Day 1 and had no effect on Day 4 when midazolam was co-administered as a single oral dose of 2 mg on Days 1 and 4.
Croatian: Fosaprepitant 150 mg primijenjen u jednokratnoj intravenskoj dozi 1. dana liječenja zajedno s pojedinačnim peroralnim dozama od 2 mg midazolama 1. i 4. dana liječenja, povisio je AUC0-∞ midazolama za 77% 1. dana, a nije imao učinka 4. dana.
English: The aprepitant regimen consisted of aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 and 3 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1 and 8 mg daily on Days 2 through 4.
Croatian: Režim liječenja aprepitantom sastojao se od 125 mg aprepitanta 1. dana te 80 mg/dan 2. i 3. dana liječenja, u kombinaciji s ondanzetronom 32 mg primijenjenim intravenski 1. dana liječenja i deksametazonom u dozi od 12 mg 1. dana te 8 mg 2. do 4. dana liječenja.
English: When administered intravenously fosaprepitant is rapidly converted to aprepitant.
Croatian: Nakon intravenske primjene fosaprepitant vrlo brzo prelazi u aprepitant.
English: Respiratory, thoracic and mediastinal disorders hiccups common oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation rare
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja štucanje često orofaringealna bol, kihanje, kašalj, sekrecija iz nosa u ždrijelo, nadraženo grlo rijetko
English: Vascular disorders hot flush/flushing uncommon
Croatian: Krvožilni poremećaji navale vrućine/crvenila manje često
English: Nervous system disorders headache common dizziness, somnolence uncommon cognitive disorder, lethargy, dysgeusia rare
Croatian: Učestalost kognitivni poremećaj, letargija, disgeuzija rijetko
English: 6 - < 12 years old
Croatian: U dobi od 6 do < 12 godina
English: 5 mg/kg intravenously
Croatian: 5 mg/kg intravenski
English: §§Delayed phase = 25 to 120 hours post-initiation of cisplatin chemotherapy.
Croatian: Kasnija faza = 25 do 120 sati nakon započinjanja kemoterapije cisplatinom.
English: *Primary endpoint is bolded.
Croatian: *Primarna mjera ishoda označena je masno otisnutim slovima.
English: The fosaprepitant 150 mg single dose did not induce CYP3A4 on Days 1 and 4 in the midazolam interaction study.
Croatian: U ispitivanju interakcije s midazolamom, fosaprepitant 150 mg u jednokratnoj dozi nije inducirao CYP3A4 1. i 4. dana liječenja.
English: Aprepitant is not excreted unchanged in urine.
Croatian: Aprepitant se putem mokraće izlučuje samo u promijenjenom obliku.
English: 3 mg/kg intravenously
Croatian: 3 mg/kg intravenski
English: No data are available following the administration of a 3-day IV fosaprepitant regimen in paediatric patients.
Croatian: Nema dostupnih podataka za pedijatrijske bolesnike nakon trodnevnog režima samo intravenske primjene fosaprepitanta.
English: Avoid shaking and jetting sodium chloride 9 mg/ml (0.9 %) solution for injection into the vial.
Croatian: Nemojte tresti bočicu niti naglo ubrizgati 0,9%-tnu (9 mg/ml) otopinu natrijeva klorida za injekciju.
English: VIAL LABEL 150 mg
Croatian: NALJEPNICA BOČICE 150 mg
English: §§Acute= 0 to 24 hours post-initiation of chemotherapy.
Croatian: §§Akutna faza= 0 do 24 sata nakon započinjanja kemoterapije.
English: Sodium hydroxide (E524) (for pH adjustment) and/or Hydrochloric acid diluted (E507) (for pH adjustment)
Croatian: 6.1 Popis pomoćnih tvari dinatrijev edetat (E386) polisorbat 80 (E433) laktoza, bezvodna natrijev hidroksid (E524) (za podešavanje pH) i/ili kloridna kiselina, razrijeđena (E507) (za podešavanje pH)
English: Slovenská republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com
Croatian: Česká republika Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com
English: 4 mg/kg intravenously
Croatian: 4 mg/kg intravenski
English: : 800 00 673 (+357 22866700) cyprus_info@merck.com
Croatian: Merck Sharp & Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com
English: The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1, 8 mg on Day 2, and 8 mg twice daily on Days 3 and 4.
Croatian: Režim liječenja fosaprepitantom sastojao se od jedne doze fosaprepitanta od 150 mg 1. dana liječenja, u kombinaciji s ondanzetronom 32 mg primijenjenim intravenski 1. dana liječenja i deksametazonom u dozi od 12 mg 1. dana, 8 mg 2. dana te 8 mg dvaput na dan 3. i 4. dana liječenja.
English: General disorders and administration site conditions infusion site erythema, infusion site pain, infusion site pruritus uncommon infusion site induration rare immediate hypersensitivity reactions including flushing, erythema, dyspnoea, anaphylactic reactions/anaphylactic shock not known
Croatian: manje često induracija na mjestu infuzije rijetko trenutne reakcije preosjetljivosti uključujući navale crvenila, eritem, dispneju, anafilaktičke reakcije/anafilaktički šok nepoznato
English: Plasma concentrations of fosaprepitant are below quantifiable levels within 30 minutes of the completion of infusion.
Croatian: Tijekom 30 minuta od završetka infuzije, koncentracije fosaprepitanta u plazmi snize se ispod mjerljive granice.
English: Mild injection site thrombosis has been observed at higher doses without concomitant vesicant chemotherapy.
Croatian: Pri primjeni viših doza bez istodobne kemoterapije vezikantom zabilježeni su slučajevi blage tromboze na mjestu primjene infuzije.
English: Fosaprepitant regimen (N =1,106) **
Croatian: (N =1106) **
English: Tel: +48 22 549 51 00 msdpolska@merck.com
Croatian: MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the use of fosaprepitant (see section 4.5).
Croatian: Dok traje liječenje fosaprepitantom i dva mjeseca nakon uzimanja posljednje doze fosaprepitanta treba dodatno koristiti zamjenske nehormonske metode kontracepcije (vidjeti dio 4.5).
English: See the package leaflet for further information.
Croatian: Za dodatne informacije pročitati uputu o lijeku.
English: Refer to the Summary of Product Characteristics of co-administered 5-HT3 antagonist medicinal products.
Croatian: Za pravilno doziranje vidjeti uputu o lijeku odabranih 5-HT3 antagonista.
English: Dizziness and fatigue may occur following administration of IVEMEND (see section 4.8).
Croatian: Nakon primjene lijeka IVEMEND mogu se javiti omaglica i umor (vidjeti dio 4.8).
English: 5-HT3 antagonists
Croatian: Antagonist 5-HT3
English: In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [
Croatian: Unutar 72 sata od jednokratne intravenske primjene C]-fosaprepitanta (prolijeka aprepitanta) u dozi od 100 mg u zdravih i mladih odraslih osoba, oko 19% radioaktivnosti u plazmi otpada na aprepitant, što ukazuje na znatnu prisutnost njegovih metabolita u plazmi.
English: No dose adjustment is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.
Croatian: U bolesnika s oštećenjem funkcije bubrega niti u bolesnika s ESRD-om koji su na hemodijalizi nije potrebno prilagođavati dozu lijeka.
English: Renal and urinary disorders dysuria uncommon pollakisuria rare
Croatian: Poremećaji bubrega i mokraćnog sustava dizurija manje često polakizurija rijetko
English: Chemotherapeutic medicinal products
Croatian: Kemoterapeutici
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with fosaprepitant and for 2 months following the use of fosaprepitant.
Croatian: Dok traje liječenje fosaprepitantom i dva mjeseca nakon uzimanja posljednje doze fosaprepitanta treba dodatno koristiti zamjenske nehormonske metode kontracepcije.
English: What IVEMEND contains - The active substance is fosaprepitant.
Croatian: • Djelatna tvar je fosaprepitant.
English: Fosaprepitant was rapidly converted to aprepitant in in vitro incubations with liver preparations from humans.
Croatian: U in vitro inkubacijama s pripravcima metaboličkih enzima ljudske jetre, fosaprepitant se brzo pretvarao u aprepitant.
English: General disorders and administration site conditions fatigue common asthaenia, malaise uncommon oedema, chest discomfort, gait disturbance rare
Croatian: Opći poremećaji i reakcije na mjestu primjene umor često astenija, slabost manje često edem, osjećaj nelagode u prsištu, poremećaj hoda rijetko
English: Merck Sharp & Dohme B.V. Waarderweg 39
Croatian: Merck Sharp & Dohme BV Waarderweg 39, 2031 BN Haarlem Nizozemska
English: Each vial contains fosaprepitant dimeglumine equivalent to 150 mg fosaprepitant.
Croatian: Jedna bočica sadrži 150 mg fosaprepitanta u obliku fosaprepitantdimeglumina.
English: It is important to tell your doctor if you are breastfeeding or are planning to breast-feed before receiving this medicine.
Croatian: Važno je da prije početka liječenja ovim lijekom obavijestite liječnika ako dojite ili namjeravate dojiti.
English: The fosaprepitant regimen consisted of fosaprepitant 150 mg on Day 1 in combination with oral ondansetron 8 mg for 2 doses and oral dexamethasone 12 mg. On Days 2 and 3, patients in the fosaprepitant group received placebo for ondansetron every 12 hours.
Croatian: Režim s fosaprepitantom sastojao se od fosaprepitanta u dozi od 150 mg 1. dana u kombinaciji s peroralno primijenjenim ondanzetronom u dozi od 8 mg za 2 doze i peroralno primijenjenim deksametazonom u dozi od 12 mg.